Soubrier M, et al. - A comparative analysis was pursued of the retention rates of anti-tumor necrosis factor (anti-TNF) treatment (etanercept [ETN], adalimumab [ADA] and infliximab [IFX]) initiated as first-line biotherapy for rheumatoid arthritis (RA). In addition, it gauged the switch to another anti-TNF or a non-anti-TNF biological, in case of failure. No variation was noted in the retention among the three anti-TNF agents. 25% of patients continued them at 15 years. Following the failure of an anti-TNF, the switch to a non-anti-TNF biotherapy illustrated better retention.